Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 6581–6588 | Cite as

Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients

  • Xin Wei
  • Yangqiu Jin
  • Yinpu Tian
  • Huiyuan Zhang
  • Jie Wu
  • Wei Lu
  • Xiaofen Lu
Original Article

Abstract

Multiple factors in the tumor microenvironment were found to inhibit antitumor adaptive immune responses, allowing tumor persistence and growth. In this study, ascites from ovarian cancer patients were collected. We observed that a population of interleukin-10+ B (IL-10+ B) cells was preferentially enriched in the ascites. This population was associated with naive B cell phenotype or IgM or class-switched memory B cell phenotypes. The frequencies of IL-10+ B cells were negatively correlated with the frequencies of interferon gamma-producing (IFN-g+) CD8+ T cells and were positively correlated with the frequencies of Foxp3+ CD4+ T cells. To examine whether increased IL-10+ B cells in ascites could directly result in increased suppression of IFN-g production by CD8+ T cells, we cocultured CD8+ T cells with autologous blood B cells or ascitic B cells and found that CD8+ T cells cocultured with ascitic B cells demonstrated significantly suppressed IFN-g production. This suppression was in part mediated by IL-10 as well as low CD80/CD86 expression, since depletion of IL-10 and stimulation of CD28 partially reverted IL-10+ B cell-mediated suppression. Together, these data demonstrated an additional regulatory mechanism in the tumor microenvironment, which utilizes IL-10+ B cells.

Keywords

B cell Ovarian cancer 

Notes

Acknowledgments

This work was supported by Shandong Provincial Medical and Health Science Technology Development Project (2014WS0011) and Jinan Science Technology Development Project (2014–34).

Conflicts of interest

None

References

  1. 1.
    Brichard VG, Lejeune D. GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine. 2007;25:B61–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17916463.CrossRefPubMedGoogle Scholar
  2. 2.
    van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Topalian SL, Hom SS, Kawakami Y, Mancini M, Schwartzentruber DJ, Zakut R, et al. Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J Immunother. 1992;12:203–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1445813.CrossRefPubMedGoogle Scholar
  4. 4.
    Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995;2:45–59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7600302.CrossRefPubMedGoogle Scholar
  5. 5.
    Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116. Available from: http://stm.sciencemag.org/content/5/200/200ra116.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved; Available from: http://dx.doi.org/10.1038/nature14011.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25:214–21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3636159&tool=pmcentrez&rendertype=abstract.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Nishikawa H, Jäger E, Ritter G, Old LJ, Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 2005;106:1008–11.CrossRefPubMedGoogle Scholar
  9. 9.
    Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61. Elsevier. Available from: http://www.cell.com/article/S1074761314002301/fulltext.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16585599.CrossRefPubMedGoogle Scholar
  11. 11.
    Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther. 2010;10:47–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20014885.CrossRefPubMedGoogle Scholar
  12. 12.
    Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27—memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18:3281–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008;222:101–16. Available from: http://onlinelibrary.wiley.com.ezproxy.library.uvic.ca/doi/10.1111/j.1600-065X.2008.00614.x/abstract.CrossRefPubMedGoogle Scholar
  14. 14.
    Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–43.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010;32:129–40. Available from: http://www.hubmed.org/display.cgi?uids=20079667.CrossRefPubMedGoogle Scholar
  16. 16.
    Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185:4977–82.CrossRefPubMedGoogle Scholar
  17. 17.
    Sayi A, Kohler E, Toller IM, Flavell RA, Müller W, Roers A, et al. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol. 2011;186:878–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21149607.CrossRefPubMedGoogle Scholar
  18. 18.
    Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN, Fallon PG. Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol. 2004;173:6346–56.CrossRefPubMedGoogle Scholar
  19. 19.
    Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci U S A. 2007;104:14080–5.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lemoine S, Morva A, Youinou P, Jamin C. Human T cells induce their own regulation through activation of B cells. J Autoimmun. 2011;36:228–38. Available from: http://dx.doi.org/10.1016/j.jaut.2011.01.005.CrossRefPubMedGoogle Scholar
  21. 21.
    Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res. 2011;71:3505–15. Available from: http://cancerres.aacrjournals.org/content/71/10/3505.full.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006;66:7741–7. Available from: http://www.hubmed.org/display.cgi?uids=16885377.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu J, Zhan W, Kim CJ, Clayton K, Zhao H, Lee E, et al. IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses. PLoS One. 2014;9(2):e89236. Available from: http://www.hubmed.org/display.cgi?uids=24586620.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118:3420–30.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Das A, Ellis G, Pallant C, Lopes ARR, Khanna P, Peppa D, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012;189:3925–35. Available from: http://www.hubmed.org/display.cgi?uids=22972930.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009;182:5982–93.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105:4390–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Zhang X. Regulatory functions of innate-like B cells. Cell Mol Immunol. 2013;10:113–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23396472.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Plebani A, Lougaris V, Soresina A, Meini A, Zunino F, Losi CG, et al. A novel immunodeficiency characterized by the exclusive presence of transitional B cells unresponsive to CpG. Immunology. 2007;121:183–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Siewe B, Stapleton JT, Martinson J, Keshavarzian A, Kazmi N, Demarais PM, et al. Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8+ T cell function in vitro. J Leukoc Biol. 2013;93:811–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23434518.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Geffroy-Luseau A, Chiron D, Descamps G, Jégo G, Amiot M, Pellat-Deceunynck C. TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol. 2011;2:83. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2011.00083/abstract.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xin Wei
    • 1
  • Yangqiu Jin
    • 2
  • Yinpu Tian
    • 3
  • Huiyuan Zhang
    • 4
  • Jie Wu
    • 5
  • Wei Lu
    • 1
  • Xiaofen Lu
    • 1
  1. 1.Department of Gynecology and ObstetricsLiaocheng People’s HospitalLiaochengChina
  2. 2.Reproductive Center, Liaocheng People’s HospitalLiaochengChina
  3. 3.Hospice, Liaocheng People’s HospitalLiaochengChina
  4. 4.Department of Internal NeurologyLiaocheng People’s HospitalLiaochengChina
  5. 5.Department of Medical AffairsThe Maternal and Child Health Hospital of Jinan CityShandongChina

Personalised recommendations